Selected article for: "disease course and mild disease course"
Author: Ting Gao; Mingdong Hu; Xiaopeng Zhang; Hongzhen Li; Lin Zhu; Hainan Liu; Qincai Dong; Zhang Zhang; Zhongyi Wang; Yong Hu; Yangbo Fu; Yanwen Jin; Kaitong Li; Songtao Zhao; Yongjiu Xiao; Shuping Luo; Lufeng Li; Lingfang Zhao; Junli Liu; Huailong Zhao; Yue Liu; Weihong Yang; Jing Peng; Xiaoyu Chen; Ping Li; Yaoning Liu; Yonghong Xie; Jibo Song; Lu Zhang; Qingjun Ma; Xiuwu Bian; Wei Chen; Xuan Liu; Qing Mao; Cheng Cao
Title: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
  • Document date: 2020_3_30
    • ID: dxs8ggyh_27
    Snippet: Secondly, Masp2 KO mice showed significantly mild symptoms and a shorter course of disease in LPS induced, N protein boosted mice pneumonia model, which confirmed the harmful 15 role of MASP-2 in this severe pneumonia. Accordingly, administration of anti-MASP-2 antibody or the MASP-2 inhibitor C1INH showed a promising treatment effect (Fig. 3) . Improved MASP-2 antibodies that have higher affinity and neutralization activity, such as OMS721 (38) .....
    Document: Secondly, Masp2 KO mice showed significantly mild symptoms and a shorter course of disease in LPS induced, N protein boosted mice pneumonia model, which confirmed the harmful 15 role of MASP-2 in this severe pneumonia. Accordingly, administration of anti-MASP-2 antibody or the MASP-2 inhibitor C1INH showed a promising treatment effect (Fig. 3) . Improved MASP-2 antibodies that have higher affinity and neutralization activity, such as OMS721 (38) (which showed promising effects on thrombotic microangiopathy), or an injectable C1INH medicine, such as HAEGARDA, may provide effective protection. Further clinical evaluation is of value to 20 be carried out for the treatment of SARS-CoV-2 induced pneumonia.

    Search related documents:
    Co phrase search for related documents
    • anti antibody administration and severe pneumonia: 1
    • anti antibody administration and treatment effect: 1
    • anti antibody and clinical evaluation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • anti antibody and effective protection: 1, 2, 3, 4
    • anti antibody and high affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • anti antibody and induced pneumonia: 1, 2, 3, 4, 5, 6, 7, 8
    • anti antibody and mouse pneumonia model: 1
    • anti antibody and neutralization activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • anti antibody and pneumonia model: 1, 2
    • anti antibody and promising effect: 1, 2
    • anti antibody and SARS induced pneumonia: 1, 2
    • anti antibody and severe pneumonia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • anti antibody and short course: 1
    • anti antibody and thrombotic microangiopathy: 1
    • anti antibody and treatment effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • clinical evaluation and disease short course: 1
    • clinical evaluation and high affinity: 1, 2, 3, 4, 5, 6, 7
    • clinical evaluation and induced pneumonia: 1, 2
    • clinical evaluation and neutralization activity: 1, 2